Though it's often portrayed as a scourge of the teen years, acne can affect people of all ages. According to the National Institutes of Health (NIH), about 80 percent of people between the ages of 11 and 30 have outbreaks of the skin disorder at some point.
"Many see their acne go away by the time they reach their 30s," says Jane Liedtka, a medical officer at the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER). "But for some, acne persists into their 40s and 50s...
On July 20, 2009, the U.S. Food and Drug Administration (FDA) announced the approval of a vaccine for the prevention of flu during the 2009-2010 influenza season in the United States.
Each year, experts from FDA, the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other institutions study influenza virus samples and patterns collected from around the world in an effort to identify the strains that may cause the most illness in the upcoming season.
Those forecasts and the recommendations of FDA’s Vaccines and Related Biological Products Advisory Committee enable FDA to determine the three strains that manufacturers should include in their seasonal vaccines for the U.S. population.
Doesn't Protect Against the 2009 (pandemic) H1N1 Influenza Virus
The newly approved influenza vaccine is directed against strains of influenza that were expected to be circulating during the 2009-2010 influenza season, based on information available in February, when a decision regarding the composition of the vaccine was made.
The seasonal flu vaccine will not protect people against the 2009 (pandemic) H1N1 influenza virus, which emerged later in the year and resulted in the declaration of a pandemic by the WHO in June 2009. FDA is working with manufacturers, international partners, and other government agencies to facilitate the availability of a safe and effective vaccine against the 2009 (pandemic) H1N1 influenza virus.
Currently Licensed Seasonal Influenza Vaccines
Although no vaccine is 100 percent effective in preventing disease, vaccination is the key to flu prevention.
The 2009-2010 seasonal influenza vaccine is available for use in the United States and through six brand names and manufacturers:
• Afluria, by CSL Limited
• Fluarix, by GlaxoSmithKline Biologicals
• FluLaval, by ID Biomedical Corp of Quebec.
• Fluvirin, by Novartis Vaccines and Diagnostics Limited
• Fluzone, by Sanofi Pasteur Inc.
• FluMist, by MedImmune, LLC
The vaccine for 2009-2010 seasonal influenza contains the following: